FORT WORTH, Texas, June 15, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today announced that its direct-to-consumer television sales program for CellerateRX® has entered rotation within the programming of the Fox News Channel. Fox News, home of such shows as The O'Reilly Factor, Hannity's America, and Geraldo at Large, will run the commercial spots throughout the programming day.
The CellerateRX commercial was produced by TV Goods, Inc and is being distributed by MED3TV, LLC. The spot contains a demonstration of how the FDA-cleared collagen based product works, while providing a medical validation of the product from Dr. Peter Demitry, specialty trained in Occupational and Environmental Medicine, Harvard University and Fellow of the Aerospace Medical Association.
Kevin Harrington, Celebrity Judge on the ABC TV show Shark Tank and Chairman of H&H Imports Inc, the parent company of TV Goods, states, "The CellerateRX story has mass appeal and needs to be heard by the largest audience possible. The Fox News Network, America's highest rated non-entertainment network, is a perfect fit for this product to reach its target audience."
According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, "Peter Lynch, the legendary former manager of the Fidelity Magellan Fund, popularized the investment philosophy of 'investing in what you know'. The Fox News placements should bring our brand and product awareness to new levels, as more and more consumers discover the benefits of CellerateRX. We are anticipating and will welcome the increased investor inquiries and interest that these spots will generate."
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com
For Further Information:
Shareholder Relations-Communications (917) 974-9872
|SOURCE Wound Management Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved